Genome editing is also being explored with CRISPR/Cas9-based gene therapy triggering SCN1A transcription in inhibitory neurons shown to ameliorate seizures in Dravet syndrome mice (Colasante et al., 2020; Yamagata et al., 2020). This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.